Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001209181
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

Submission Contact Information

Name

Phone

E-Mail Address

144: Issuer Information

Name of Issuer Roivant Sciences Ltd.

SEC File Number 001-40782

7th Floor 50 Broadway

Address of Issuer

London

UNITED KINGDOM

SW1H 0DB

Phone 207 400 3347

Name of Person for Whose Account the Securities are To Be Sold MOMTAZEE JAMES C

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Name the Securities Exchange
Common shares, \$0.0000000341740141 par value per share (??? Common Shares???)	E*TRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	687	7000.53	771742197	10/17/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Date you Nature of Name of Is Date Amount of Date of Nature of

Class	Acquired	Acquisition Transaction	Person from Whom Acquired	Donor Acquired	Securities Acquired	Payment	Payment *
Common Shares	10/16/2023	Award of Common Shares granted under the Roivant Sciences Ltd. 2021 Equity Incentive Plan	Roivant Sciences Ltd.		687	10/16/2023 N/	A

^{*} If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
James C. Momtazee c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common Shares	09/18/2023	6752	75419.84

144: Remarks and Signature

Remarks

The securities included in Table I represent shares sold to cover the reporting person's tax obligations when an award of Common Shares belonging to the reporting person are settled. The securities included in Table II represent shares sold to cover the reporting person's tax obligations when an award of Common Shares belonging to the reporting person was settled. The securities reported in Tables I and II do not represent discretionary trades by the reporting person, and will be sold, or were sold, as applicable, for the limited purpose of satisfying tax withholding obligations.

Date of Notice 10/17/2023

Date of Plan Adoption or

Giving of Instruction, If 02/15/2022

Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Jo Chen, as Attorney-in-Fact for James C Momtazee

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)